FETUB

FETUB encodes fetuin-B, a liver-secreted glycoprotein that functions as a cysteine protease inhibitor with broad roles in fertility, metabolic homeostasis, and inflammation. Its best-characterized function is potent inhibition of the metalloproteinase ovastacin (ASTL), preventing premature zona pellucida hardening; genetic epistasis in mice confirmed that the infertility of Fetub-knockout females is fully rescued by concomitant ovastacin deficiency (PMID:27733488). FETUB also inhibits neprilysin (NEP) enzymatic activity in the airway, where its knockdown restores NEP function and alleviates asthma-related inflammation (PMID:40064057), and it physically interacts with insulin receptor-β to suppress PI3K/Akt signaling, promoting insulin resistance and NF-κB-driven inflammation in retinal and microglial cells (PMID:39382879, PMID:37883127). Hepatic FETUB transcription is positively regulated by the leptin–STAT3 axis and negatively regulated by the vitamin D receptor, and FETUB modulates hepatocyte lipogenesis and pyroptosis through the NLRP3/GSDMD pathway (PMID:35896788, PMID:29684480, PMID:22739111, PMID:41506566).

1. 2012 Medium

   Establishing that FETUB has a hepatocyte-intrinsic metabolic function: siRNA knockdown in liver cells showed FETUB suppresses lipogenic gene expression and lipid accumulation, revealing it as a negative regulator of lipogenesis beyond its known protease-inhibitor identity.

   Evidence siRNA knockdown in Chang liver cells with lipid and gene expression readouts

   PMID:22739111

   Open questions at the time

   • Downstream lipogenic targets not identified
   • No in vivo confirmation of anti-lipogenic role
   • Mechanism of lipogenesis suppression unknown
2. 2016 High

   Identifying the primary physiological target of fetuin-B: genetic rescue experiments showed that fertility defects of Fetub-knockout female mice are entirely dependent on ovastacin (ASTL), establishing fetuin-B as the endogenous inhibitor that prevents premature zona pellucida hardening and is essential for fertilization.

   Evidence Fetub−/−; Astl−/− double-knockout rescue in mice, antisense oligonucleotide knockdown, IVF assays

   PMID:27733488

   Open questions at the time

   • Structural basis of FETUB–ovastacin interaction not experimentally resolved
   • Whether fetuin-B also inhibits other metzincin proteinases in vivo unknown
3. 2018 Medium

   Demonstrating transcriptional control of FETUB by vitamin D signaling: 1α,25-(OH)₂D₃ suppresses FETUB expression in hepatocellular cells in a VDR-dependent manner, providing a regulatory link between vitamin D status and circulating fetuin-B levels.

   Evidence Hepatocellular cell treatment with calcitriol, VDR silencing, mouse vitamin D supplementation, ELISA

   PMID:29684480

   Open questions at the time

   • VDR binding site on FETUB promoter not mapped
   • Physiological significance of VDR-FETUB axis in whole-organism metabolism unclear
4. 2020 Medium

   Revealing FETUB as an upstream suppressor of PI3K/AKT signaling with tumor-suppressive consequences: overexpression in prostate cancer cells inhibited proliferation and invasion, effects reversed by a PI3K activator, placing FETUB functionally upstream of PI3K/AKT.

   Evidence Lentiviral overexpression, xenograft model, 740Y-P rescue, Western blot

   PMID:32892030

   Open questions at the time

   • Direct molecular target mediating PI3K suppression in cancer cells not identified
   • Not confirmed in additional cancer types
   • Endogenous FETUB expression in prostate tissue not characterized
5. 2022 Medium

   Linking leptin–STAT3 signaling to FETUB transcription: leptin stimulates FETUB expression in hepatocytes through STAT3 binding to the FETUB promoter, integrating fetuin-B into the adiposity–liver cross-talk axis.

   Evidence Leptin stimulation of primary hepatocytes/AML12 cells, STAT3 inhibition, promoter binding analysis

   PMID:35896788

   Open questions at the time

   • Quantitative contribution of STAT3 versus other transcription factors not resolved
   • In vivo validation of leptin–FETUB axis in obesity models limited
6. 2024 Medium

   Establishing a direct physical interaction between FETUB and insulin receptor-β and its functional consequence: FETUB binds IRβ, and this interaction increases under high glucose, suppressing PI3K/Akt signaling and promoting insulin resistance and NF-κB-mediated inflammation in retinal microglia and Müller cells.

   Evidence Co-immunoprecipitation, recombinant FETUB and shRNA knockdown in BV2 and Müller cells, PI3K inhibitor rescue, Western blot, diabetic retinopathy mouse model

   PMID:37883127 PMID:39382879

   Open questions at the time

   • Binding interface between FETUB and IRβ not mapped
   • Whether FETUB–IRβ interaction occurs in non-retinal tissues in vivo unknown
   • Independent replication needed
7. 2025 High

   Expanding protease-inhibitor repertoire: FETUB directly inhibits neprilysin (NEP) enzymatic activity, and lung-specific FETUB knockdown in asthma models restored NEP activity, reduced neuropeptide accumulation, and alleviated airway inflammation and hyperresponsiveness.

   Evidence Molecular docking, protein binding assay, fluorescence substrate NEP activity assay, AAV-mediated lung-specific FETUB knockdown in mice

   PMID:40064057

   Open questions at the time

   • Kinetic parameters (Ki) of FETUB–NEP inhibition not reported
   • Whether FETUB inhibits NEP in other tissues not tested
8. 2026 Medium

   Elucidating FETUB's role in MASH-associated pyroptosis: free fatty acids upregulate FETUB in hepatocytes, which downregulates AdipoR1 to activate the NLRP3/GSDMD pyroptotic pathway; FETUB blockade ameliorates steatohepatitis in vivo.

   Evidence Primary hepatocyte FFA stimulation, FETUB blockade in HFD mouse model, NLRP3/GSDMD pathway Western blot, histology

   PMID:41506566

   Open questions at the time

   • Mechanism by which FETUB downregulates AdipoR1 not defined
   • Single lab; independent replication needed
9. 2026 Medium

   Clarifying fetuin-B handling in the reproductive system: granulosa cells do not synthesize fetuin-B but internalize it from serum and re-secrete it in a regulated manner, indicating a paracrine delivery mechanism to the oocyte.

   Evidence RT-qPCR, ELISA, immunocytochemistry of cultured granulosa cells versus HepG2 control

   PMID:41577932

   Open questions at the time

   • Receptor or uptake mechanism for fetuin-B internalization by granulosa cells unknown
   • Functional consequence of regulated release timing not tested

• The structural basis of FETUB's dual protease inhibition (ovastacin and neprilysin), the molecular mechanism by which it modulates IRβ and AdipoR1, and whether its metabolic and inflammatory effects are mediated through a single or multiple receptor interactions remain unresolved.
• No crystal structure of FETUB or FETUB–target complexes
• No unified model connecting protease-inhibitor and receptor-modulatory functions
• Tissue-specific contributions of circulating versus locally released FETUB not dissected